SEARCH:   Advanced

Blood, 1 October 2004, Vol. 104, No. 7, pp. 2124-2133. Prepublished online as a Blood First Edition Paper on June 10, 2004; DOI 10.1182/blood-2004-01-0064. This Article Full Text (PDF) All Versions of this Article: 2004-01-0064v1 104/7/2124    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Saudemont, A. Articles by Quesnel, B. Search for Related Content PubMed PubMed Citation Articles by Saudemont, A. Articles by Quesnel, B. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 7, 2004 Accepted May 16, 2004 In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis Aurore Saudemont and Bruno Quesnel* Unite INSERM 524, Institut de Recherche sur le Cancer de Lille, Lille, France; Institut Federatif de Recherche 114, Lille, France Unite INSERM 524, Institut de Recherche sur le Cancer de Lille, Lille, France; Institut Federatif de Recherche 114, Lille, France; Service des Maladies du Sang, Centre Hospitalier et Universitaire de Lille, Lille, France * Corresponding author; email: brunoquesnel{at}hotmail.com. In tumor dormancy, tumor cells persist in the host over a long period of time, but do not grow. We investigated in the DA1-3b mouse model of acute myeloid leukemia how leukemic cells could persist for months in spite of an effective anti-leukemic immune response. Mice were immunized with irradiated IL12- or CD154- transduced DA1-3b cells, and then challenged with wild type DA1-3b cells, and were randomly killed during one year follow-up. Quantification of residual disease one year after challenge showed that persistent leukemic cells represented less than 0.02 % of spleen cells in most animals. These residual cells were still able to kill naive hosts, even when isolated after one year of persistence. Persistent leukemic cells were more resistant to specific CTL-mediated killing, and had enhanced B7-H1 and B7.1 expression, proportional to the time they had persisted in the host. Blocking B7-H1 or B7.1/CTLA-4 interaction enhanced CTL-mediated killing of the persistent cells, and blocking B7-H1, B7.1, or CTLA-4 in vivo prolonged survival of naive mice injected with persistent leukemic cells. Thus, escape of leukemic cells from tumor immunity via over-expression of B7-H1 or B7.1 might represent a new mechanism of tumor dormancy in acute leukemia. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Mumprecht, C. Schurch, J. Schwaller, M. Solenthaler, and A. F. Ochsenbein Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression Blood, August 20, 2009; 114(8): 1528 - 1536. [Abstract] [Full Text] [PDF] J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood, July 1, 2007; 110(1): 296 - 304. [Abstract] [Full Text] [PDF] Y. Waeckerle-Men, A. Starke, and R. P. Wuthrich PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+cytotoxic T cells Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1527 - 1536. [Abstract] [Full Text] [PDF] A. Saudemont, A. Hamrouni, P. Marchetti, J. Liu, N. Jouy, D. Hetuin, F. Colucci, and B. Quesnel Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1 Cancer Res., May 1, 2007; 67(9): 4491 - 4498. [Abstract] [Full Text] [PDF] I. Tirapu, E. Huarte, C. Guiducci, A. Arina, M. Zaratiegui, O. Murillo, A. Gonzalez, C. Berasain, P. Berraondo, P. Fortes, et al. Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma Cancer Res., February 15, 2006; 66(4): 2442 - 2450. [Abstract] [Full Text] [PDF] L. Chen B7-H1 connection of innate and adaptive immunity against tumor dormancy Blood, March 15, 2005; 105(6): 2242 - 2243. [Full Text] [PDF] A. Saudemont, N. Jouy, D. Hetuin, and B. Quesnel NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells Blood, March 15, 2005; 105(6): 2428 - 2435. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020